Trade Report: The McKinley Carter Wealth Services Inc. Sold shares of Johnson & Johnson (JNJ)

The McKinley Carter Wealth Services Inc. Sold shares of Johnson & Johnson (JNJ)

McKinley Carter Wealth Services Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.9% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 6,896 shares of the company’s stock after selling 590 shares during the period. McKinley Carter Wealth Services Inc.’s holdings in Johnson & Johnson were worth $836,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Stratford Consulting LLC boosted its position in shares of Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 3,201 shares of the company’s stock worth $388,000 after buying an additional 18 shares during the last quarter. Gateway Advisory LLC boosted its position in shares of Johnson & Johnson by 0.5% in the first quarter. Gateway Advisory LLC now owns 4,215 shares of the company’s stock worth $456,000 after buying an additional 23 shares during the last quarter. Bollard Group LLC boosted its position in shares of Johnson & Johnson by 0.7% in the second quarter. Bollard Group LLC now owns 3,895 shares of the company’s stock worth $473,000 after buying an additional 27 shares during the last quarter. Armbruster Capital Management Inc. boosted its position in shares of Johnson & Johnson by 0.7% in the second quarter. Armbruster Capital Management Inc. now owns 4,438 shares of the company’s stock worth $538,000 after buying an additional 30 shares during the last quarter. Finally, Amarillo National Bank boosted its position in shares of Johnson & Johnson by 0.6% in the second quarter. Amarillo National Bank now owns 5,496 shares of the company’s stock worth $667,000 after buying an additional 35 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) traded down 0.32% during mid-day trading on Friday, reaching $115.33. 8,813,324 shares of the company traded hands. Johnson & Johnson has a 52-week low of $94.28 and a 52-week high of $126.07. The stock has a 50 day moving average price of $117.51 and a 200-day moving average price of $117.79. The company has a market capitalization of $315.53 billion, a P/E ratio of 20.24 and a beta of 0.62.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.66 by $0.02. The business earned $17.80 billion during the quarter, compared to analyst estimates of $17.71 billion. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.36%. The firm’s revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.49 earnings per share. Analysts expect that Johnson & Johnson will post $6.72 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be given a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.77%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date of this dividend is Friday, November 18th. Johnson & Johnson’s dividend payout ratio is 56.64%.

A number of equities analysts have issued reports on JNJ shares. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 target price for the company in a research report on Monday, August 22nd. Barclays PLC restated an “overweight” rating and set a $125.00 target price (up previously from $120.00) on shares of Johnson & Johnson in a research report on Sunday, July 10th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price for the company in a research report on Friday, August 5th. BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, September 7th. Finally, Jefferies Group boosted their price objective on shares of Johnson & Johnson from $109.00 to $113.00 and gave the company a “hold” rating in a research report on Thursday, July 14th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $120.98.

In other Johnson & Johnson news, Director Charles Prince acquired 875 shares of the business’s stock in a transaction that occurred on Friday, October 21st. The shares were purchased at an average price of $114.11 per share, with a total value of $99,846.25. Following the completion of the transaction, the director now owns 26,520 shares in the company, valued at $3,026,197.20. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Related posts

Leave a Comment